Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4455-4462

  Nadler, Yasmine ^a   Camp, Robert L ^a   Schwartz, Candice ^a   Rimm, David L ^a   Kluger, Harriet M ^a   Kluger, Yuval ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CYTOKERATIN; AURORA KINASE; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ADULT; AGED; BIOSYNTHESIS; FEMALE; HISTORY; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HISTORY, 17TH CENTURY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 51649095478     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5268     Document Type: Article

References (41)

1. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36.
2. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10.
3. Kimura M, Kotani S, Hattori T, et al. Cell cycledependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast IpII. J Biol Chem 1997; 272:13766-71.
4. Terada Y, Tatsuka M, Suzuki F, Yasuda Y, Fujita S, Otsu M. AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J 1998;17:667-76.
5. Kimura M, Matsuda Y, Yoshioka T, Sumi N, Okano Y Identification and characterization of STK12/Aik2: a human gene related to Aurora of Drosophila and yeast IPL1. Cytogenet Cell Genet 1998;82:147-52.
6. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (Aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49-54.
7. Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003;4: 842-54.
8. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001;2: 21-32.
9. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17: 3052-65.
10. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999;91:1160-2.
11. Tatsuka M, Katayama H, Ota T et al. Multinuclearity and increased ploidy caused by overexpression of the Aurora- and IpII - like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811-6.
12. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-93.
13. Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59: 249-63.
14. Harrington EA, Bebbington D, Moore J, et al. VX- 680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
15. Marumoto T, Zhang D, Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer 2005;5:42-50.
16. Warner SL. Bearss DJ, Han H. Von Hoff DD. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003; 2:589-95
17. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-80.
18. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161:281-94.
19. Dewar H, Tanaka K, Nasmyth K, Tanaka TU. Tension between two kinetochores suffices for their bi-orientation on the mitotic spindle. Nature 2004;428:93-7
20. Wang X, Zhou YX, Qiao W, et al. Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25:7148-58.
21. Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/Aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control 2006;17:81-3.
22. Fletcher O, Johnson N, Palles C, et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006; 98:1014-8.
23. Dai Q, Cai QY Shu XO, et al. Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:2065-70.
24. 2 to M transition. J Biol Chem 2004;279:19643-8.
25. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999;59:2041-4.
26. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001;92:370-3.
27. Hoque A, Carter J, Xia W, et al. Loss of Aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 2003:12: 1518-22.
28. Royce ME, Xia W, Sahin AA, et al. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004; 100:12-9.
29. Ruiz-Cortes ZT, Kimmins S, Monaco L, Burns KH, Sassone-Corsi P, Murphy BD. Estrogen mediates phosphorylation of histone H3 in ovarian follicle and mammary epithelial tumor cells via the mitotic kinase, Aurora B. Mol Endocrinol 2005;19:2991-3000.
30. 2-M phase progression in human breast cancer cells via the down-regulation of cyclin B1 and survivin expression. Breast Cancer Res Treat 2007;102:263-73.
31. Soncini C, Carpinelli P. Gianellini L, et al. PHA- 680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006;12: 4080-9.
32. Tchatchou S, Wirtenberger M, Hemminki K, et al. Aurora kinases A and B and familial breast cancer risk. Cancer Lett 2007;247:266-72.
33. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome Cancer Res 2003;63:1445-8.
34. Camp RL, Chung GG, Rimm DL Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8: 1323-7.
35. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome Cancer Res 2006;66:5487-94
36. Lassmann S, Shen Y Jutting U, et al Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res 2007;13:4083-91
37. Zeng WF, Navaratne K, Prayson RA, Weil RJ. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 2007; 60:218-21.
38. Kurai M, Shiozawa T, Shih HC, et al Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 2005;36:1281-8.
39. Fisher B, Dignam J. Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997: 89:1673-82.
40. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42
41. Fisher B, Redmond C. Legault-Poisson S. et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005-18.